tetano
Editor, Senior Moderator
Front Immunol
. 2025 Jun 25:16:1578733.
doi: 10.3389/fimmu.2025.1578733. eCollection 2025. Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines
Chengyu Hu[SUP] #[/SUP][SUP] 1 [/SUP], Chenguang Niu[SUP] #[/SUP][SUP] 1 [/SUP], Xiaohui Li[SUP] #[/SUP][SUP] 1 [/SUP], Ke He[SUP] 2 [/SUP], Mengyu Li[SUP] 2 [/SUP], Xiaonan Gao[SUP] 2 [/SUP], Qiannan Wei[SUP] 1 [/SUP], Weiyang Sun[SUP] 3 [/SUP], Yongkun Zhao[SUP] 3 [/SUP], Yuanguo Li[SUP] 3 [/SUP], Xianzhu Xia[SUP] 3 4 [/SUP], Zhiguang Ren[SUP] 1 2 3 [/SUP], Xiaodong Li[SUP] 1 [/SUP], Tiecheng Wang[SUP] 3 4 [/SUP]
Affiliations
COVID-19 and seasonal influenza have taken a huge toll on the global economy and global health. Given the potential of COVID-19 to transform into a chronic epidemic akin to seasonal influenza, the influenza virus and SARS-CoV-2 will continue to be a significant threat to healthcare for some time to come. Coinfection involving the two viruses has been proven to worsen the severity of the illness, as evidenced by clinical observational data. Vaccination remains the most effective measure in the prevention and treatment of infectious diseases. In addition, the coadministration of influenza virus and SARS-CoV-2 vaccines offered greater benefits than either vaccine alone. Combination vaccines are also a major hotspot in novel vaccine development. This review highlights the advancements in the development of combined vaccines for COVID-19 and seasonal influenza, as demonstrated in animal studies and clinical trials, and emphasizes the importance of a combined vaccine.
Keywords: SARS-CoV-2; coadministration; coinfection; combination vaccines; influenza virus.
. 2025 Jun 25:16:1578733.
doi: 10.3389/fimmu.2025.1578733. eCollection 2025. Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines
Chengyu Hu[SUP] #[/SUP][SUP] 1 [/SUP], Chenguang Niu[SUP] #[/SUP][SUP] 1 [/SUP], Xiaohui Li[SUP] #[/SUP][SUP] 1 [/SUP], Ke He[SUP] 2 [/SUP], Mengyu Li[SUP] 2 [/SUP], Xiaonan Gao[SUP] 2 [/SUP], Qiannan Wei[SUP] 1 [/SUP], Weiyang Sun[SUP] 3 [/SUP], Yongkun Zhao[SUP] 3 [/SUP], Yuanguo Li[SUP] 3 [/SUP], Xianzhu Xia[SUP] 3 4 [/SUP], Zhiguang Ren[SUP] 1 2 3 [/SUP], Xiaodong Li[SUP] 1 [/SUP], Tiecheng Wang[SUP] 3 4 [/SUP]
Affiliations
- PMID: 40636108
- PMCID: PMC12238597
- DOI: 10.3389/fimmu.2025.1578733
COVID-19 and seasonal influenza have taken a huge toll on the global economy and global health. Given the potential of COVID-19 to transform into a chronic epidemic akin to seasonal influenza, the influenza virus and SARS-CoV-2 will continue to be a significant threat to healthcare for some time to come. Coinfection involving the two viruses has been proven to worsen the severity of the illness, as evidenced by clinical observational data. Vaccination remains the most effective measure in the prevention and treatment of infectious diseases. In addition, the coadministration of influenza virus and SARS-CoV-2 vaccines offered greater benefits than either vaccine alone. Combination vaccines are also a major hotspot in novel vaccine development. This review highlights the advancements in the development of combined vaccines for COVID-19 and seasonal influenza, as demonstrated in animal studies and clinical trials, and emphasizes the importance of a combined vaccine.
Keywords: SARS-CoV-2; coadministration; coinfection; combination vaccines; influenza virus.